California Grand Ballroom

 

[7:45-8:00 AM] Welcome to IWWM-13

Ranjana Advani, Stephen Ansell, Prashant Kapoor, and Steven Treon [Workshop Organizers]

 

 

[8:00-9:00 AM] Session I

Genomic Predispositions in WM

Tina Bagratuni, Zachary Hunter [Chairs]

 

Single Cell Analysis reveals multiple monoclonal populations in WM and its precursor stages

Minghao Dang, MD Anderson, United States

 

Multiclonal Disease Underlies Familial WM

Alberto Guijosa, Dana Farber Cancer Institute United States

 

Spatial Profiling Reveals Tumor Microenvironmental Alterations in Asymptomatic WM progression

Irene Ghobrial, Dana Farber Cancer Institute United States

 

Importance of 6Q loss revealed in a MYD88 Transgenic Model of WM

Filip Garbicz, Dana Farber Cancer Institute United States

 

Panel Discussion, All Session I Speakers

 

 

[9:00-10:00 AM] Session II

Genomic Landscape of the WM Clone

Damien Roos-Weil, Romanos Pistofidis-Sklavenitis [Chairs]

 

Genomic Evolution of WM across disease stages

Jithma Abeykoon, Mayo Clinic-Rochester, United States

 

Time dependent genomic evolution of WM revealed in the E-Score

Zachary Hunter, Dana Farber Cancer Institute, United States

 

Subtype specific evolutionary Trajectories in WM

Gareth Morgan, New York University-Langone, United States

 

Secondary genomic alterations associated with MYD88 driven oncogenesis

Maria Luisa Guerrera, Dana Farber Cancer Institute, United States

 

Panel Discussion, All Session II Speakers

 

[10:00-10:30 AM] Mid-Morning Break & Networking

Ballroom Terrace

 

[10:30-11:30 AM] Session III

High Risk Genomics in WM

Gareth Morgan, Ramon Garcia Sanz [Chairs]

 

Prognostic Significance of TP53 Mutations from the BIOWM Study

Marzia Varettoni, University of Pavia, Italy

 

Genomic Landscape of High-Risk WM Disease

David Moreno, University of Barcelona, Spain

 

High Risk Genomics in the Era of BTK-Inhibitors

Shuhui Yi, Chinese Academy of Medical Sciences, China

 

Double HIT TP53 Alterations Define Ultra High-Risk WM

Steve Treon, Dana Farber Cancer Institute, United States

 

Panel Discussion, All Session III Speakers

 

 

[11:30-12:30 PM] Session IV

Tumor Immune Microenvironment

Stephen Ansell, Samir Parekh [Chairs]

 

Evolution of Tumor Immune Microenvironment

Romanos Pistofidis-Sklavenitis, City of Hope, United States

 

 

Tumor Immune Microenvironmental Interactions in WM

Hao Sun, Dana Farber Cancer Institute, United States

 

Role of Myeloid derived Immune Cells in WM related Immune Suppression

Patricia Mondello, Mayo Clinic-Rochester, United States

 

Distinct Immune and Genomic Signatures Predict Resistance to Ibrutinib Therapy in Waldenstrom’s macroglobulinemia

Tina Bagratuni, University of Athens, Greece

 

Panel Discussion, All Session IV Speakers

 

 

[12:30-1:30 PM] LUNCH

San Jacinto-Santa Rosa Hall

 

Consensus Panel Breakout Sessions (For Panel Members)

CHINO Conference Room

 

PANEL 1: Defining Uniform Criteria for MRD Assessment in WM

PANEL 2: Response Criteria for Non-IgM LPL Incl. Hyposecretory/Non-secretory

 

 

[1:30-2:30 PM] Session: V

Signaling Networks and Novel Targets in WM

Ken Anderson, Noopur Raje [Chairs]

 

Targeting IRAK signaling in MYD88 Mutated Lymphomas

John Hatcher, Dana Farber Cancer Institute, United States

 

Targeting HCK in BTK-Inhibitor resistant MYD88 Mutates Lymphomas

Shirong Liu, Dana Farber Cancer Institute, United States

 

Mechanistic Insights into Abrogating T-Cell exhaustion from A MYD88 Mutated Transgenic Murine Model

Christelle Vincent-Faber, University of Limoges, France

 

Targeting Alarmins to Improve T-Cell Immunity and Cellular Therapy Outcomes in MM: Lessons for WM

Samir Parekh, MT Sinai Medical Center, United States

 

Panel Discussion, All Session V Speakers

 

 

[2:30-3:30 PM] Session: VI

Plenary Session I

Oral Presentations- Basic and Translational

Nikhil Munshi, Marzia Varettoni [Chairs]

 

Presentations- TBD

Speaker-TBD

 

Presentations- TBD

Speaker-TBD

 

Presentations- TBD

Speaker-TBD

 

Presentations- TBD

Speaker-TBD

 

[3:10 PM] Panel Discussion, All Session VI Speakers

 

[3:30-4:00 PM] Session VII 

Keynote Lecture

 

AI Powered Workflows for Blood Cancers

Keynote Speaker: Jansen Seheult, Mayo Clinic-Rochester, United States

Keynote Moderator: Stephen Ansell, Mayo Clinic-Rochester, United States

 

[4:00-4:30 PM] Afternoon Break & Networking

Ballroom Terrace

 

[6:00-10:00 PM] Opening Ceremonies and Awards Presentation

Palm Springs Art Museum

[5:30-6:00 PM] Buses depart from the Hotel

 

• Keynote Speaker: BeiGene, Inc.
• Presentation of the Peter S. Bing Humanitarian Award
• Presentation of Jan Gosta Waldenstrom Award
• Presentation of Robert A. Kyle Award

California Grand Ballroom

 

[8:00-9:00 AM] Session VIII

Special Topics in WM

Stathis Kastritis, Jorge Castillo [Chairs]

 

Management of Transformed WM

Eric Durot, CHU DE REIMS, France

 

Management of IgM Peripheral Neuropathy

Shayna Sarosiek, Dana Farber Cancer Institute, United States

 

Management of Bing Neel Syndrome

Naohiro Sekiguchi, National Disaster Medical Center, Japan

 

Management of WM related Amyloidosis

Monique Minnema, University of Utrecht, The Netherlands

 

Panel Discussion, All Session VIII Speakers

 

 

[9:00-10:00 AM] Session IX

Novel Approaches for Treatment Naïve WM- Clinical Studies I

Meletios Dimopoulos, Judith Trotman [Chairs]       

 

Prospective Randomized Study of DRC vs. Bortezomib-DRC (ECWM-1 Trial) in Treatment naïve WM

Pierre Morel, CHU Amiens Picardie, France

 

Prospective Study of Bortezomib, Ibrutinib and Rituximab (ECWM-2 Trial) in Treatment naïve WM

Christian Buske, University of Ulm, Germany

 

Prospective Study of Ibrutinib and Carfilzomib vs. Ibrutinib (CZAR-1) in Treatment naïve WM

Stathis Kastritis, University of Athens, Greece

 

Randomized Phase II Study of DRC vs. Venetoclax and Rituximab (VIWA-1 Trial) in Treatment naïve WM

Christian Buske, University of Ulm, Germany

 

Panel Discussion, All Session IX Speakers

 

 

[10:00-10:30 AM] Mid-Morning Break & Networking

Ballroom Terrace

 

 

[10:30-11:30 AM] Session X

Novel Approaches for Treatment naïve WM-Clinical Studies II

M.J. Kersten, Constantine Tam [Chairs]

 

Prospective Study of Bendamustine-Rituximab followed by Observation or maintenance Rituximab

Mathias Rummel, University of Giessen, Germany

 

Prospective Study of Bendamustine, Rituximab and Acalabrutinib in Treatment naïve WM

Neil Berinstein, Sunnybrook Health Sciences Center, Canada

 

Prospective Study of Bendamustine, Rituximab and Zanubrutinib in Treatment naïve WM-China Study

Lugui Qiu, Chinese Academy of Medical Sciences, China

 

Prospective Study of Bendamustine, Rituximab and Zanubrutinib in Treatment naïve WM- USA Study

Andrew Branagan, Massachusetts General Hospital, United States

 

Panel Discussion, All Session X Speakers

 

[11:30-12:30] Session XI

Novel Approaches for Previously Treated WM

Moshe Gatt, Sheeba Thomas [Chairs]

 

Prospective Study of Pirtobrutinib monotherapy in previously treated WM

1. Lia Palomba, Memorial Sloane Kettering Cancer Center, United States

 

Prospective Study of Pirtobrutinib and Venetoclax in previously treated WM

Jorge Castillo, Dana Farber Cancer Institute, United States

 

Phase I Study of the BTK PROTAC BGB-16673 in relapsed refractory WM

Anna Maria Frustaci, Duerre Congressi Srl, Italy

 

Prospective Study of the CD19-ADC Loncastuximab in Previously Treated WM

Shayna Sarosiek, Dana Farber Cancer Institute, United States

 

Panel Discussion, All Session XI Speakers

 

 

[12:30-1:30 PM] LUNCH

San Jacinto-Santa Rosa Hall

 

Consensus Panel Breakout Sessions (For Panel Members)

CHINO Conference Room

 

PANEL 3: Management of Peripheral Neuropathy in WM and IgM related Disorders

PANEL 4: Updated Recommendations for Management of Treatment naïve, symptomatic WM

 

[12:30-1:30 PM] Young Investigator Mentoring LUNCH

San Jacinto Conference Room

 

[1:30-2:30 PM] Session: XII

Plenary Session II

Oral Presentations- Clinical Studies

Ranjana Advani, Evangelos Terpos [Chairs]

 

Presentations- TBD

Speaker-TBD

 

Presentations- TBD

Speaker-TBD

 

Presentations- TBD

Speaker-TBD

 

Presentations- TBD

Speaker-TBD

 

Panel Discussion, All Session XII Speakers

 

 

[2:30-3:30 PM] Session XIII

Plenary Session III

Young Investigator [YIA] Oral Presentations

Andrew Branagan, Josephine Vos [Chairs]

 

Presentations- TBD

Speaker-TBD

 

Presentations- TBD

Speaker-TBD

 

Presentations- TBD

Speaker-TBD

 

Presentations- TBD

Speaker-TBD

 

Panel Discussion, All Session XIII Speakers

 

[3:30-5:00 PM] Session XIV

Poster Session & Reception

Sierra-Ventura Hall

 

[6:00-8:00 PM] Faculty Dinner Reception- Thompson Palm Springs

[6:00-10:00 PM} Palm Springs Street Fair Festival, Palm Canyon Drive

[5:30 PM] Departure in the Hotel Lobby

California Grand Ballroom

 

[8:00-9:30 AM] Session XV

Great Debates in WM

Eva Kimby & Irene Ghobrial [Chairs]

 

[8:00-8:20 AM] Great Debate I

Should Family of Patients with Inherited WM Predisposition be Evaluated for WM and Related Disorders?

 

YES!  They should be evaluated

Sigurdur Kristinson, University of Iceland, Iceland

 

NO!  They should NOT be evaluated

M.J Kersten, University of Amsterdam, The Netherlands

 

 

[8:20-8:40 AM] Great Debate II

Should TP53 Mutation Status be considered in Treatment Decisions?

 

YES! They should be considered

Jorge Castillo, Dana Farber Cancer Institute, United States

 

NO! They should NOT be considered

Christian Buske, University of Ulm, Germany

 

[8:40-9:00] Great Debate III

Should Chemo-immunotherapy be used before or after BTK-Inhibitors in WM?

 

They should be used BEFORE BTK Inhibitors

Meletios Dimopoulos, University of Athens, Greece

 

They should be used AFTER BTK Inhibitors

Alessandra Tedeschi, Niguarda Hospital, Italy

 

[9:00-9:20 AM] Great Debate IV

Do we still need stem cell transplantation in the era of targeted and cellular therapies in WM?

 

NO, we do not need stem cell transplantation

Constantine Tam, Alfred Hospital, Monash University, Australia

 

YES, we DO need stem cell transplantation

Charalampia Kyriakou, University College London Hospitals NHS Trust, United Kingdom

 

 

[9:30-10:00 AM] Mid-Morning Break & Networking

Ballroom Terrace

 

[10:00-11:00 AM] Session XVI

Clinical Trials in Progress for WM- Non-Cellular Therapies

Jeffrey Matous, Roger Owen [Chairs]

 

Randomized Clinical Trial of Ibrutinib vs. DRC in Treatment naïve WM: RAINBOW Trial

Rebecca Auer, Royal London Hospital, United Kingdom

 

Prospective Study of Pirtobrutinib, Rituximab, and Venetoclax (PROVEN Study) in Treatment naïve WM

1. Lia Palomba, Memorial Sloane Kettering Cancer Center, United States

 

Phase 2 Study of the BCL2 Inhibitor Sonrotoclax in relapsed refractory WM

Ramon Garcia Sanz, Universitario Gregorio Maranon De Madrid, Spain

 

Clinical Trial of Sonrotoclax and BGB-16673 in Treatment naïve and BTK-Inhibitor naïve WM: Sounder Trial

Judith Trotman, University of Sydney, Australia

 

Panel Discussion, All Session XVI Speakers

 

 

[11:00-3:30 PM] BLISS FAMILY WORKSHOP for Advancing Cellular Therapies in WM

 

[11:00-11:30 PM] Session XVII 

 

Keynote Lecture 1

Bringing Cellular Therapies to WM: The Lymphoma Experience

Keynote Speaker: Steven Schuster, UC Health Cancer Care, United States

Keynote Moderator: Ranjana Advani, Stanford University, United States

 

Keynote Lecture 2

Bringing Cellular Therapies to WM: The Myeloma Experience

Keynote Speaker: Noopur Raje, Mass General Hospital, United States

Keynote Moderator: Prashant Kapoor, Mayo Clinic-Rochester, United States

 

[11:30-12:30 PM] LUNCH

San Jacinto-Santa Rosa Hall

 

Consensus Panel Breakout Sessions (For Panel Members)

CHINO Conference Room

 

PANEL 5: Updated Recommendations for Management of Relapsed-Refractory WM

PANEL 6: Targets and Priorities for Advancing Cellular Therapies in WM

 

[12:30-1:30 PM] Session XVIII

Clinical Trials in Progress for WM- Cellular Therapies I

Hermann Einsele, Edward Stadtmauer [Chairs]

 

Clinical Trial of the CD19 TCE AZD0486 in Previously Treated WM

Tarek Mouhieddine, Dana Farber Cancer Institute, United States

 

Clinical Trial of the CD20 TCE Epcoritamab in previously treated WM- USA Experience

Gottfried von Keudell, Beth Israel Deaconess Medical Center, United States

 

Clinical Trial of the CD20 TCE Epcoritamab in previously treated WM- European Experience

Josephine Vos, University of Amsterdam, The Netherlands

 

Randomized Study of Odronextamab vs. Odronextamab and Zanubrutinib in WM: MOZART TRIAL

Christian Buske, University of Ulm, Germany

 

Panel Discussion, All Session XVIII Speakers

 

 

[1:30-2:30 PM] Session XIX

Clinical Trials in Progress for WM- Cellular Therapies II

Steven Schuster, Noopur Raje [Chairs]

 

Clinical Trial of the BCMA TCE Etentamig in Previously Treated WM

Prashant Kapoor, Mayo Clinic-Rochester, United States

 

Clinical Trial of the BCMA TCE Teclistamab in Previously Treated WM

Andrew Branagan, Mass General Hospital, United States

 

Clinical Trial of Mosunetuzumab and Pirtobrutinib in previously treated WM

Narendranath Epperla, University of Utah, United States

 

Prospective Study of Epcoritamab and Zanubrutinib in Treatment naïve, Symptomatic WM

Camille Edwards, Dana Farber Cancer Institute, United States

 

Panel Discussion, All Session XIX Speakers

 

 

[2:30-3:30 PM] Session XX

Advisory Panel on Advancing Cellular Therapies in WM

Stephen Ansell, Steven Treon [Chairs] 

 

Prioritizing TCE and CAR T cell studies in WM: Which Options, and for Which patients?

Hermann Einsele, University of Wurzburg, Germany

 

Developing MRD response assessment tools for dynamic risk assessment in WM

Nikhil Munshi, Dana Farber Cancer Institute, United States

 

What’s next in the world of Cellular Therapies that WM can serve as a disease model?

Eric Smith, Dana Farber Cancer Institute, United States

 

Can animal models help us identify and optimize cellular therapy options for WM?

Jose Martinz-Climent, University of Navarra, Spain

 

Panel Discussion, All Session XX Speakers

 

 

[3:30-4:00 PM] Afternoon Break & Networking

Ballroom Terrace

[6:00-10:00 PM] Closing Ceremonies and Awards Presentation

Westin Rancho Mirage

 

[5:30-6:00 PM] Buses depart from the Hotel

 

• Presentation of the Young Investigator Awards
• Announcement and Welcome to IWWM-14, 2028

Mojave Learning Center

 

[8:00-9:00 AM] Morning Break & Networking

Ballroom Terrace

 

[9:00-12:00 PM] Session XXI

IWWM & IWMF WM Patient

 

Highlights of IWWM-13 for WM Patients & Caregivers

Ranjana Advani, Prashant Kapoor [Chairs]

 

[9:00 AM] Introductions

Paul Kitchen, International Waldenstrom’s Macroglobulinemia Foundation

Delora Senft, International Waldenstrom’s Macroglobulinemia Foundation

 

[9:15 AM] Progress in Genomics and Personalized Treatment Approaches for WM

Tina Bagratuni, University of Athens, Greece

Zachary Hunter, Dana Farber Cancer Institute, United States

 

[9:45 AM] New Targets and Drug Development Opportunities

Romanos Sklavenitis-Pistofidis, City of Hope, United States

John Hatcher, Dana Farber Cancer Institute, United States

 

[10:15 AM] Highlights of Clinical Trials Reported at IWWM-13

Christian Buske, University of Ulm, Germany

Shayna Sarosiek, Dana Farber Cancer Institute, United States

 

[10:45 AM] The New Frontier: Cellular Therapy Trials in WM

Monique Minnema, University of Utrecht, The Netherlands

1. Lia Palomba, Memorial Sloan Kettering Cancer Center, United States

 

[11:15 AM] Summary of Great Debates in WM: What is Still Controversial, and What Do the Experts Think?

Josephine Vos, University of Amsterdam, The Netherlands

Andrew Branagan, Massachusetts General Hospital, United States

 

[11:45 AM] Conclusions

Ranjana Advani, University of Stanford, United States

Prashant Kapoor, Mayo Clinic-Rochester, United States

 

[12:00-1:00 PM] LUNCH

Catalina Hall

 

[1:00-4:00 PM] WM-NET Strategic Initiatives Meeting

CHINO Meeting room

Jorge Castillo [Chair]

 

[4:00-6:00 PM] IWMF Board Meeting

Snow Creek Board Room

 

Paul Kitchen, International Waldenstrom’s Macroglobulinemia Foundation

Delora Senft, International Waldenstrom’s Macroglobulinemia Foundation

 

[7:00-10:00 PM] WMNET- IWMF Dinner Reception, Melvyn’s

[6:30 PM] Buses depart from the Hotel, by invitation